Dopamine D1 receptor ligands: Where are we now and where are we going

@article{Zhang2009DopamineDR,
  title={Dopamine D1 receptor ligands: Where are we now and where are we going},
  author={Jing Zhang and Bing Xiong and Xuechu Zhen and Ao Zhang},
  journal={Medicinal Research Reviews},
  year={2009},
  volume={29}
}
The dopamine (DA) D1 receptor is the most highly expressed DA receptor subtype among the DA receptor family. Although the first DA D1 receptor selective ligand SCH‐23390 (1) was introduced more than two decades ago, clinically useful D1 receptor selective ligands are rare. A renewed interest was ignited in the early 1990s by Nichols and Mailman who developed dihydrexidine (27a), the first high affinity full efficacy agonist for the D1 receptor. Since then, a number of D1 receptor agonists with… Expand
Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics.
TLDR
The major classes of D1R selective ligands including antagonists, orthosteric agonists, non-catechol biased agonists and positive allosteric modulators are reviewed, highlighting their structure-activity relationships and medicinal chemistry. Expand
A Complete Assessment of Dopamine Receptor- Ligand Interactions through Computational Methods
TLDR
This in silico approach was successful in showing known receptor-ligand interactions as well as in determining unique combinations of interactions, which will support mutagenesis studies to improve the design of subtype-specific ligands. Expand
Ligand-Specific Roles for Transmembrane 5 Serine Residues in the Binding and Efficacy of Dopamine D1 Receptor Catechol Agonists
TLDR
The hypothesis that the decreased D1 activity of chroman analogs results from a ligand intramolecular hydrogen bond that impairs the ability of the catechol to engage the receptor is supported. Expand
D1-like receptors distinguishing thieno-azecine regioisomers
Designing ligands with D1/D5 subtype selectivity is a challenge because of the high identity within the receptor helices. Based on the lead compounds 1–3, the thieno-benzazecine regioisomers 4 and 5Expand
Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes
TLDR
Five cryoelectron microscopy structures of the dopamine D1 receptor coupled to Gs heterotrimer in complex with three catechol-based agonists, a non-catechol agonist, and a positive allosteric modulator for endogenous dopamine revealed that a polar interaction network is essential for Catecholamine-like agonist recognition and specific motifs in the extended binding pocket were responsible for discriminating D1- from D2-like receptors. Expand
MS Binding Assays for D1 and D5 Dopamine Receptors
TLDR
Results obtained indicate that the established MS Binding Assays addressing D1 and D5 receptors are well‐suited substitutes for radioligand binding assays, the technique that has so far dominated affinity determinations toward these targets. Expand
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation
TLDR
PF-6142 improved performance in rodent models of NMDA receptor antagonist-induced cognitive dysfunction, and reversed ketamine-induced deficits in NHP performing the spatial delayed recognition task, and did not alter the efficacy of risperidone in assays predictive of antipsychotic-like effect in rodents including pre-pulse inhibition and conditioned avoidance responding. Expand
Gs- versus Golf-dependent functional selectivity mediated by the dopamine D1 receptor
TLDR
The findings of Gs/Golf-dependent functional selectivity in D1R ligands open a new avenue for the treatment of cortex-specific or striatum-specific neuropsychiatric dysfunction. Expand
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder
TLDR
Findings lend further clinical support to the potential of D1 receptor agonists to treat schizophrenia-spectrum working memory impairments, and suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery. Expand
Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors
TLDR
A reversed stereoselectivity for the enantiomers of DOX at D(1) and alpha(2C) receptors is demonstrated and have implications for the therapeutic utility of doxanthrine. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Dihydrexidine--the first full dopamine D1 receptor agonist.
TLDR
An updated overview of the pharmacology of dihydrexidine is provided and possible clinical utility of dopamine D(1) receptor agonists in various central nervous system disorders is discussed. Expand
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum
TLDR
The hypothesis that the antiparkinsonian effect of dopamine receptor agonists is mediated by a more complex interactions with dopamine receptor subtypes than currently believed is supported. Expand
The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors.
TLDR
In monkey and human cells, SKF 83959 did not stimulate cyclic adenosine monophosphate (cAMP) formation to a significant extent, but antagonized very potently the dopamine-induced stimulation of cAMP formation in both cell types. Expand
Parkinson's disease and D1 dopamine receptors.
TLDR
The role of the D1-like dopamine receptors in Parkinson's disease (PD) is reviewed, an idea supported by the location of D1 receptors in key aspects of basal ganglia circuitry, and scientific advances have suggested that therapeutic profiles may be improved. Expand
Recent advances towards the discovery of dopamine receptor ligands
TLDR
This review provides an overview of the recent patent literature during 2003 – 2005 on the development of therapeutic agents, mainly targeting the five dopamine receptors. Expand
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
The present work provides a detailed pharmacological characterization of dihydrexidine (DHX) (trans-10,11-dihydroxy- 5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine), the first high-potency, fullExpand
SCH 23390: the first selective dopamine D1-like receptor antagonist.
  • J. Bourne
  • Biology, Medicine
  • CNS drug reviews
  • 2001
TLDR
Previous in vivo pharmacological studies with SCH 23390 have shown it to abolish generalized seizures evoked by the chemoconvulsants: pilocarpine and soman, providing evidence of the potential importance of D1-like dopaminergic receptor mechanisms in facilitating the initiation and spread of seizures. Expand
Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists
TLDR
The intrinsic activities of selected dopamine D1 receptor agonists were compared in three distinct molecular expression systems, C‐6, Ltk, and GH4, cells transfected with primate D1A receptors, demonstrating significant and biologically meaningful differences in intrinsic efficacy. Expand
Dopamine receptors: from structure to function.
TLDR
Target deletion of several of these dopamine receptor genes in mice should provide valuable information about their physiological functions and provide unequivocal evidence for the involvement of one of these receptors in the etiology of various central nervous system disorders. Expand
Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions
TLDR
It is hypothesized that dyskinesia is linked to PLC stimulation, andDA D1 agonism can play a role in the induction of psychosis, via a mechanism linked neither to AC nor PLC, and DA D1 antagonists differ in antipsychotic potential, possibly via this unidentified mechanism. Expand
...
1
2
3
4
5
...